JPMorgan lowered the firm’s price target on Molecular Partners (MLLCF) to CHF 3 from CHF 3.50 and keeps a Neutral rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLLCF:
- Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
- Molecular Partners presents updated data from Phase 1/2a trial of MP0533
- Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
- Molecular Partners presents new MP0712 data
- Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating